Physician profile
Gary Hodge
NPI 1801457064
$11,473.44
in general payments reported to CMS, 2019-2025
29 companies · $653 in 2025
The $653 reported for 2025 was more than what 86% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.05 · 2020: $14.64 · 2021: $86.05 · 2022: $10K · 2023: $55.92 · 2024: $535 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $10,000.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $234.41 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Arcutis Biotherapeutics, INC. | $224.28 | 2024 | Zoryve |
| Lilly USA, LLC | $198.58 | 2024-2025 | Ebglyss, Mounjaro, Zepbound |
| Novo Nordisk INC | $77.81 | 2024-2025 | Ozempic, Wegovy |
| Abbvie INC. | $61.69 | 2024-2025 | |
| Exact Sciences Corporation | $58.32 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bioventus LLC | $52.18 | 2022 | |
| Phathom Pharmaceuticals, INC. | $47.37 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.37 | 2020-2022 | |
| Djo, LLC | $38.89 | 2023 | Donjoy, Aircast |
| Sanofi Pasteur INC. | $38.88 | 2025 | |
| Janssen Biotech, INC. | $38.77 | 2024 | Tremfya |
| Revance Therapeutics, INC. | $38.16 | 2024 | Daxxify |
| Glaxosmithkline, LLC. | $34.76 | 2025 | Arexvy, Trelegy Ellipta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $31.74 | 2024-2025 | |
| Boston Scientific Corporation | $30.97 | 2024 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $21.75 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.39 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $19.98 | 2024 | Trintellix |
| Amarin Pharma, INC. | $19.94 | 2019 | |
| Corium, LLC | $17.72 | 2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $17.11 | 2021 | |
| Heron Therapeutics, INC. | $17.03 | 2023 | Zynrelef |
| Dexcom, INC. | $15.44 | 2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $14.88 | 2024 | Intellis Adaptivestim |
| Allergan, INC. | $14.13 | 2021 | |
| Corcept Therapeutics | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Hodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.